Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Mount Sinai Hospital
mi
from
New York, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Montefiore Medical Center
mi
from
Bronx, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.
Status: Enrolling
Updated:  7/28/2015
Women and Infants Hospital
mi
from
Providence, RI
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.
Status: Enrolling
Updated: 7/28/2015
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma
Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Hepatocellular Carcinoma: A Pilot Study
Status: Enrolling
Updated:  7/28/2015
University of California at San Francisco
mi
from
San Francisco, CA
Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma
Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Hepatocellular Carcinoma: A Pilot Study
Status: Enrolling
Updated: 7/28/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated:  7/28/2015
Florida Cancer Specialists-North
mi
from
St. Petersburg, FL
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated: 7/28/2015
Florida Cancer Specialists-North
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated:  7/28/2015
Florida Cancer Specialists South
mi
from
Ft. Myers, FL
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated: 7/28/2015
Florida Cancer Specialists South
mi
from
Ft. Myers, FL
Click here to add this to my saved trials
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated:  7/28/2015
Nebraska Methodist Hospital
mi
from
Omaha, NE
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated: 7/28/2015
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated:  7/28/2015
Research Medical Center
mi
from
Kansas City, MO
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated: 7/28/2015
Research Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated:  7/28/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated: 7/28/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated:  7/28/2015
Woodlands Medical Center
mi
from
Pensacola, FL
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated: 7/28/2015
Woodlands Medical Center
mi
from
Pensacola, FL
Click here to add this to my saved trials
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated:  7/28/2015
Yale School of Medicine
mi
from
New Haven, CT
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated: 7/28/2015
Yale School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated:  7/28/2015
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Status: Enrolling
Updated: 7/28/2015
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status: Enrolling
Updated:  7/28/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status: Enrolling
Updated: 7/28/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status: Enrolling
Updated:  7/28/2015
Grady Memorial Hospital
mi
from
Atlanta, GA
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status: Enrolling
Updated: 7/28/2015
Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status: Enrolling
Updated:  7/28/2015
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status: Enrolling
Updated: 7/28/2015
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status: Enrolling
Updated:  7/28/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Status: Enrolling
Updated: 7/28/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy
Status: Enrolling
Updated:  7/28/2015
The Mayo Clinic
mi
from
Rochester, MN
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy
Status: Enrolling
Updated: 7/28/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Phase II Open Label Trial of rIL-2 and Bevacizumab Combination in Patients With Metastatic Clear Cell Renal Carcinoma
Status: Enrolling
Updated:  7/28/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Phase II Open Label Trial of rIL-2 and Bevacizumab Combination in Patients With Metastatic Clear Cell Renal Carcinoma
Status: Enrolling
Updated: 7/28/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Autologous Redirected RNA Meso-CIR T Cells
Phase 1 Clinical Trial of Autologous Mesothelin Re-Directed T Cells Administered Intravenously in Patients With Progressive Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  7/29/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Autologous Redirected RNA Meso-CIR T Cells
Phase 1 Clinical Trial of Autologous Mesothelin Re-Directed T Cells Administered Intravenously in Patients With Progressive Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 7/29/2015
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status: Enrolling
Updated:  7/29/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status: Enrolling
Updated: 7/29/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status: Enrolling
Updated:  7/29/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status: Enrolling
Updated: 7/29/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status: Enrolling
Updated:  7/29/2015
UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status: Enrolling
Updated: 7/29/2015
UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status: Enrolling
Updated:  7/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status: Enrolling
Updated: 7/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Baltimore, MD
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Boston, MA
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
New York, NY
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Oklahoma City, OK
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Nashville, TN
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Houston, TX
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Toronto,
A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795
A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Toronto,
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Detroit, MI
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Lebanon, NH
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Durham, NC
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/30/2015
GSK Investigational Site
mi
from
Salt Lake City, UT
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/30/2015
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated:  7/30/2015
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated: 7/30/2015
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated:  7/30/2015
Northeast Georgia Cancer Care
mi
from
Athens, GA
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated: 7/30/2015
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated:  7/30/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated: 7/30/2015
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated:  7/30/2015
The West Clinic, PC
mi
from
Memphis, TN
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
Status: Enrolling
Updated: 7/30/2015
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated:  7/30/2015
Clinical Research Facility
mi
from
Oceanside, CA
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated: 7/30/2015
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated:  7/30/2015
Clinical Research Facility
mi
from
Santa Rosa, CA
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated: 7/30/2015
Clinical Research Facility
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated:  7/30/2015
Research Site
mi
from
Seongnam,
TAURAS - T790 AURA ScreenFailure SOC Registry Study
TAURAS - T790 AURA ScreenFailure SOC Registry Study
Status: Enrolling
Updated: 7/30/2015
Research Site
mi
from
Seongnam,
Click here to add this to my saved trials
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated:  7/30/2015
Northeast Alabama Regional Medical Center
mi
from
Anniston, AL
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated: 7/30/2015
Northeast Alabama Regional Medical Center
mi
from
Anniston, AL
Click here to add this to my saved trials
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated:  7/30/2015
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated: 7/30/2015
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated:  7/30/2015
Naval Medical Center - San Diego
mi
from
San Diego, CA
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated: 7/30/2015
Naval Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated:  7/30/2015
Veterans Affairs Medical Center - San Diego
mi
from
San Diego, CA
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated: 7/30/2015
Veterans Affairs Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated:  7/30/2015
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated: 7/30/2015
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated:  7/30/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated: 7/30/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated:  7/30/2015
Walter Reed Army Medical Center
mi
from
Washington,
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated: 7/30/2015
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated:  7/30/2015
Veterans Affairs Medical Center - Washington, DC
mi
from
Washington,
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated: 7/30/2015
Veterans Affairs Medical Center - Washington, DC
mi
from
Washington,
Click here to add this to my saved trials
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated:  7/30/2015
Broward General Medical Center
mi
from
Fort Lauderdale, FL
Surgery in Treating Patients With Prostate Cancer
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial
Status: Enrolling
Updated: 7/30/2015
Broward General Medical Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials